Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan-Mar;11(1):10-16.
doi: 10.4103/0259-1162.179313.

Perioperative Considerations and Management of Patients Receiving Anticoagulants

Safiya Imtiaz Shaikh  1 , R Vasantha Kumari  1 , Ganapati Hegade  1 , M Marutheesh  1
Affiliations
Review

Perioperative Considerations and Management of Patients Receiving Anticoagulants

Safiya Imtiaz Shaikh et al. Anesth Essays Res. 2017 Jan-Mar.

Abstract

Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis. Unfractionated heparin, low molecular weight heparin (LMWH), fondaparinux, and warfarin have been studied and employed extensively with direct thrombin inhibitors typically reserved for patients with complications or those requiring interventions. Novel oral anticoagulants have emerged from clinical development and are expected to replace older agents with their ease to use and more favorable pharmacodynamic profiles. Increasingly, anesthesiologists are being requested to anesthetize patients who are on some form of anticoagulants and hence it is important to have sound understanding of pharmacology, dosing, monitoring, and toxicity of anticoagulants. We searched the online databases including PubMed Central, Cochrane, and Google Scholar using anticoagulants, perioperative management, anesthetic considerations, and LMWH as keywords for the articles published between 1994 and 2015 while writing this review. In this article, we will review the different classes of anticoagulants and how to manage them in the perioperative settings.

Keywords: Anesthetic considerations; anticoagulants; low molecular weight heparin; perioperative management.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition) Reg Anesth Pain Med. 2010;35:64–101. - PubMed
    1. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. European Scoeity of Anaesthesiology. Regional anaesthesia and antithrombotic agents: Recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999–1015. - PubMed
    1. Breivik H, Bang U, Jalonen J, Vigfússon G, Alahuhta S, Lagerkranser M. Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand. 2010;54:16–41. - PubMed
    1. Gómez-Outes A, Avendaño-Solá C, Terleira-Fernández AI, Vargas-Castrillón E. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. Pharmacoeconomics. 2014;32:919–36. - PubMed
    1. Baglin T. Clinical use of new oral anticoagulant drugs: Dabigatran and rivaroxaban. Br J Haematol. 2013;163:160–7. - PubMed